Supplementary Table 2 from A Pilot Study of the CD38 Antagonist Daratumumab in Patients with Metastatic Renal Cell Carcinoma or Muscle-Invasive Bladder Cancer
Year: 2025
Type: supplementary-materials
Abstract: All Adverse Events in the mRCC cohort regardless of attribution
Authors: Matthew T. Campbell, Amishi Y. Shah, Pavlos Msaouel, Nizar M. Tannir, Arlene O. Siefker-Radtke, Ashish M. Kamat, Neema Navai, Colin P.N. Dinney, Priya Rao, Charles C. Guo, Rahul A. Sheth, Aradhana M. Venkatesan, Rebecca S. Tidwell, Shalini S. Yadav, Aidi Gu, Hong Chen, Marc Macaluso, Fei Duan, Sreyashi Basu, Sonali Jindal, Padmanee Sharma
Language: English
Subfield: Pulmonary and Respiratory Medicine
Field: Medicine
Domain: Health Sciences
Open Access status: gold
OpenAlex ID: W4409139399